PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

BPC-157: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for BPC-157 across studied indications.

Back to BPC-157 overview

Research Summary

A 2025 systematic review of 36 studies (35 preclinical, 1 clinical) found consistent evidence for musculoskeletal healing in animal models, but noted a critical lack of human data. One clinical study showed 7/12 patients with chronic knee pain experienced relief for over six months after a single injection. A 2025 IV safety pilot in 2 healthy adults (up to 20 mg) reported zero adverse events. A Phase II RCT (NCT07437547) for acute hamstring strain is currently recruiting 120 participants in China (2026). The compound's dual VEGFR2/eNOS pathway mechanism is well-characterized in vitro, but translation to human clinical outcomes remains the key evidence gap.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Musculoskeletal healing Tier C 0 Extensive animal data, no human RCTs
Gut healing Tier C 0 Strong preclinical GI protection data
Tendon repair Tier C 0 Animal models show accelerated healing

Graded using our evidence tier methodology.

Citations (8 sources)

  1. 1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review Review

    Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025), Orthopaedic Journal of Sports Medicine

  2. 2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review Review

    Józwiak M, et al. (2025), Pharmaceuticals

  3. 3. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway Study

    Hsieh MJ, Liu HT, Wang CN, et al. (2020), Scientific Reports

  4. 4. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications Review

    Sikiric P, et al. (2018), Current Neuropharmacology

  5. 5. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Review

    Gwyer D, Wragg NM, Wilson SL (2019), Cell and Tissue Research

  6. 6. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157 Review

    Seiwerth S, et al. (2012), Current Pharmaceutical Design

  7. 7. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Clinical Trial

    Multiple authors (2025), Clinical Pharmacology

  8. 8. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress Study

    Sikiric P, et al. (1997), Digestive Diseases and Sciences